The Permeability of Puerarin Loaded Poly(butylcyanoacrylate) Nanoparticles Coated with Polysorbate 80 on the Blood–Brain Barrier and Its Protective Effect against Cerebral Ischemia/Reperfusion Injury

Zhao, Lei; Liu, Anchang; Yu, Shuwen; Wang, Zeng-xin; Lin, Xiaoqian; Zhai, Guangxi; Zhang, Qing-zhu

doi:10.1248/bpb.b12-00769

Cited by 52 publications

(32 citation statements)

References 45 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coating polysorbate 80 to the surface of nanoparticles has been shown to enhance the efficiency for nanoparticles to interact with BBB through the following mechanisms: (1) binding with apolipoprotein E in the blood and the follow-up endocytosis by endothelial cells, and (2) suppressing the function of P-glycoprotein (P-gp), consequently reducing the efflux of nanoparticles from brain parenchyma [67]. Recent studies have successfully applied this concept both in therapeutics and diagnostics [66, 67]. These polysorbate 80 coated nanoparticles could significantly increase the brain uptake of doxorubicin at 1 hour post administration (nanoparticle with doxorubicin: undetectable amount, polysorbate 80 coated nanoparticle with doxorubicin: 2 µg/g) [87].…”

Section: 1 Targeting Endothelial Cells In the Cnsmentioning

confidence: 99%

Targeting specific cells in the brain with nanomedicines for CNS therapies

Zhang¹,

Lin²,

Kannan

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

Treatment of Central Nervous System (CNS) disorders still remains a major clinical challenge. The Blood-brain-barrier (BBB), known as the major hindrance, greatly limits therapeutics penetration into the brain. Moreover, even though some therapeutics can cross BBB based on their intrinsic properties or via the use of proper nanoscale delivery vehicles, their therapeutic efficacy is still often limited without the specific uptake of drugs by the cancer or disease-associated cells. As more studies have started to elucidate the pathological roles of major cells in the CNS (for example, microglia, neurons, and astrocytes) for different disorders, nanomedicines that can enable targeting of specific cells in these diseases may provide great potential to boost efficacy. In this review, we aim to briefly cover the pathological roles of endothelial cells, microglia, tumor-associated microglia/macrophage, neurons, astrocytes, and glioma in CNS disorders and to highlight the recent advances in nanomedicines that can target specific disease-associated cells. Furthermore, we summarized some strategies employed in nanomedicine to achieve specific cell targeting or to enhance the drug neuroprotective effects in the CNS. The specific targeting at the cellular level by nanotherapy can be a more precise and effective means not only to enhance the drug availability but also to reduce side effects.

show abstract

Section: 1 Targeting Endothelial Cells In the Cnsmentioning

confidence: 99%

Targeting specific cells in the brain with nanomedicines for CNS therapies

Zhang¹,

Lin²,

Kannan

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…In addition, utilized coated PEG-based liposomes were also found to be localized to the CA region of the hippocampus, suggesting a probable mode of targeted delivery of reactive oxidative species quenchers in the treatment of stroke (Yun et al, 2013). Zhao et al (2013) have tested Puerarin (PUE), a compound that suffers low availability in brain post-administration, as a candidate drug for treating stroke. In their work, PUE-loaded poly (butylcyanoacrylate) nanoparticles (PBCN) coated with polysorbate 80 (Ps 80), were tested for BBB crossing and effects on the cerebral ischemia/reperfusion injury.…”

Section: Different Applicationsmentioning

confidence: 99%

“…In their work, PUE-loaded poly (butylcyanoacrylate) nanoparticles (PBCN) coated with polysorbate 80 (Ps 80), were tested for BBB crossing and effects on the cerebral ischemia/reperfusion injury. It was found that the vein injection of PUE-loaded PBCN exerted an improved neuroprotective effect in rats with focal cerebral ischemic injury, significantly decreasing neurological deficit and reducing the infarct volumes (Zhao et al, 2013). Similarly, Yin et al (2012) used poly (n-butyl-2-cyanoacrylate) (PBCA) nanoparticles to deliver drugs for treatment of traumatic brain injury (TBI).…”

Section: Different Applicationsmentioning

confidence: 99%

Post-Genomics Nanotechnology Is Gaining Momentum: Nanoproteomics and Applications in Life Sciences

Kobeissy

Gülbakan

Alawieh

et al. 2014

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

The post-genomics era has brought about new Omics biotechnologies, such as proteomics and metabolomics, as well as their novel applications to personal genomics and the quantified self. These advances are now also catalyzing other and newer post-genomics innovations, leading to convergences between Omics and nanotechnology. In this work, we systematically contextualize and exemplify an emerging strand of post-genomics life sciences, namely, nanoproteomics and its applications in health and integrative biological systems. Nanotechnology has been utilized as a complementary component to revolutionize proteomics through different kinds of nanotechnology applications, including nanoporous structures, functionalized nanoparticles, quantum dots, and polymeric nanostructures. Those applications, though still in their infancy, have led to several highly sensitive diagnostics and new methods of drug delivery and targeted therapy for clinical use. The present article differs from previous analyses of nanoproteomics in that it offers an in-depth and comparative evaluation of the attendant biotechnology portfolio and their applications as seen through the lens of post-genomics life sciences and biomedicine. These include: (1) immunosensors for inflammatory, pathogenic, and autoimmune markers for infectious and autoimmune diseases, (2) amplified immunoassays for detection of cancer biomarkers, and (3) methods for targeted therapy and automatically adjusted drug delivery such as in experimental stroke and brain injury studies. As nanoproteomics becomes available both to the clinician at the bedside and the citizens who are increasingly interested in access to novel post-genomics diagnostics through initiatives such as the quantified self, we anticipate further breakthroughs in personalized and targeted medicine.

show abstract

“…This system may also permit a reduction in the dose of the compound that has poor oral bioavailability. Zhao et al (2013) reported that nano-puerarin (PN) improves the oral absorption of puerarin. In this direction, this study aims to develop PN, evaluate its anti-implantation efficacy, and map the molecular cues underlying the contragestive potential.…”

Section: Introductionmentioning

confidence: 99%

Molecular cues to the anti-implantation effect of nano-puerarin in rats

et al. 2016

View full text Add to dashboard Cite

Puerarin, a selective oestrogen receptor modulator, intercepts implantation in rats, albeit at unacceptably higher doses. We developed poly lactic-co-glycolic acid-encapsulated nano-puerarin (PN) and mapped the molecular pathway underlying its anti-implantation effects. Smooth-surfaced and spherical PN having a mean diameter of ~147 nm was obtained with good yield, efficient encapsulation, and optimum drug loading. In culture, PN slowly and steadily released puerarin, which was readily taken up by the decidual cells. PN exerted a dose-dependent anti-implantation effect. As marked by attenuated expression of stromal cell desmin, alkaline phosphatase, IGFBP1, and decidual prolactin-related protein, the anti-implantation effect of PN seemed secondary to compromised decidualization. Using in vivo (pregnant and pseudopregnant rats) and in vitro (endometrial stromal cell culture) treatment models, we document that PN enforced inhibition of uterine expression of Hbegf and Hoxa10 and their downstream signalling molecules, Cyclin D3 (CCND3)/CDK4. PN also efficiently ablated the Ihh-Nr2f2-Bmp2 signalling pathway and invited the loss of uterine potential for decidualization. There was a dose-dependent up-regulation of RHOA and its effector protein kinase, ROCK1, leading to the promotion of MLC phosphorylation and actin-myosin interaction. PN also down-regulated the stromal cell activation of ERK½ and expression of MMP9. These effects acting together stabilized the stroma and inhibited the stromal cell migration. Central to this array of events was the adversely altered endometrial expression of oestrogen receptor subtypes and repression of progesterone receptor that indulged endless proliferation of luminal epithelia and distorted the precisely choreographed stroma-epithelia crosstalk. Thus, PN dismantles the endometrial bed preparation and prevents implantation.Reproduction (2016) 151 693-707

show abstract

The Permeability of Puerarin Loaded Poly(butylcyanoacrylate) Nanoparticles Coated with Polysorbate 80 on the Blood–Brain Barrier and Its Protective Effect against Cerebral Ischemia/Reperfusion Injury

Cited by 52 publications

References 45 publications

Targeting specific cells in the brain with nanomedicines for CNS therapies

Targeting specific cells in the brain with nanomedicines for CNS therapies

Post-Genomics Nanotechnology Is Gaining Momentum: Nanoproteomics and Applications in Life Sciences

Molecular cues to the anti-implantation effect of nano-puerarin in rats

Contact Info

Product

Resources

About